To investigate disease-free survival (DFS) and prognostic factors following the administration of postoperative (chemo)radiotherapy in patients with early-stage cervical cancers.
Methods:
The medical records of 1,069 patients from 10 participating institutions were reviewed. Statistically and clinically established factors were considered as candidates for constructing the prediction model. This model was validated, using bootstrapping to correct for optimistic bias.
Results:
The 5-year DFS rate was 81.1%, with a median follow-up period of 59.6 months. The statistically significant prognostic factors were as follows: pelvic lymph node metastasis, histologic type, parametrial invasion, lymphovascular space invasion, and tumor size. The nomogram for DFS was constructed, and it demonstrated a good discrimination performance, with an internally validated concordance index of 0.72.
Conclusions:
Our predictive model exhibited accurate predictions and may be useful in designing clinical trials to study if further chemotherapy can reduce the recurrence of disease in high-risk patients.
PetersWAIIILiuPYBarrettRJIIet al.
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18(8):1606-1613.
2.
RotmanMSedlisAPiedmonteMRet al.
A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65(1):169-176.
3.
SedlisABundyBNRotmanMZLentzSSMuderspachLIZainoRJA randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73(2):177-183.
4.
KimHJRheeWJChoiSHet al.
Clinical outcomes of adjuvant radiation therapy and prognostic factors in early stage uterine cervical cancer. Radiat Oncol J. 2015;33(2):126-133.
5.
YangKParkWHuhSJBaeDSKimBGLeeJWClinical outcomes in patients treated with radiotherapy after surgery for cervical cancer. Radiat Oncol J. 2017;35(1):39-47.
6.
Van NagellJRJrRoddickJWJrLowinDMThe staging of cervical cancer: inevitable discrepancies between clinical staging and pathologic findinges. Am J Obstet Gynecol. 1971;110(7):973-978.
7.
JeHUHanSKimYSet al.
A nomogram predicting the risks of distant metastasis following postoperative radiotherapy for uterine cervical carcinoma: a Korean radiation oncology group study (KROG 1208). Radiother Oncol. 2014;111(3):437-441.
8.
KimMKJoHKongHJet al.
Postoperative nomogram predicting risk of recurrence after radical hysterectomy for early-stage cervical cancer. Int J Gynecol Cancer. 2010;20(9):1581-1586.
9.
LeeHJHanSKimYSet al.
Individualized prediction of overall survival after postoperative radiation therapy in patients with early-stage cervical cancer: a Korean Radiation Oncology Group study (KROG 1303). Int J Radiat Oncol Biol Phys. 2013;87(4):659-664.
10.
PolterauerSGrimmCHofstetterGet al.
Nomogram prediction for overall survival of patients diagnosed with cervical cancer. Br J Cancer. 2012;107(6):918-924.
11.
ZhouHLiXZhangYet al.
Establishing a Nomogram for Stage IA-IIB Cervical Cancer Patients after Complete Resection. Asian Pac J Cancer Prev. 2015;16(9):3773-3777.
12.
EifelPJMorrisMWhartonJTOswaldMJThe influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1994;29(1):9-16.
13.
AlvarezRDPotterMESoongSJet al.
Rationale for using pathologic tumor dimensions and nodal status to subclassify surgically treated stage IB cervical cancer patients. Gynecol Oncol. 1991;43(2):108-112.
14.
InoueTOkumuraMPrognostic significance of parametrial extension in patients with cervical carcinoma Stages IB, IIA, and IIB. A study of 628 cases treated by radical hysterectomy and lymphadenectomy with or without postoperative irradiation. Cancer. 1984;54(8):1714-1719.
15.
EifelPJBurkeTWMorrisMSmithTLAdenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol. 1995;59(1):38-44.
16.
GroganMThomasGMMelamedIet al.
The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 1999;86(8):1528-1536.
17.
LinDYWeiLJYingZModel-checking techniques based on cumulative residuals. Biometrics. 2002;58(1):1-12.
HeagertyPJSahaP SurvivalROC: Time-dependent ROC curve estimation from censored survival data. R package version 1.0.0. http://CRAN.R-project.org/package=survivalROC. Accessed April 11, 2017.
20.
TwuNFOuYCLiaoCIet al.
Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. Surg Oncol. 2016;25(3):229-235.
21.
DerksMBiewengaPvan der VeldenJKenterGGStalpersLJBuistMRResults of radical surgery in women with stage IB2/IIA2 cervical cancer. Acta Obstet Gynecol Scand. 2016;95(2):166-172.
22.
SongSSongCKimHJet al.
20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy. Gynecol Oncol. 2012;124(1):63-67.
23.
LiuMTHsuJCLiuWSet al.
Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy. Eur J Cancer Care (Engl). 2008;17(2):174-181.
24.
NohJMParkWKimYSet al.
Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROG 1310). Gynecol Oncol. 2014;132(3):618-623.
25.
ChenYZhangLTianJFuXRenXHaoQSignificance of the absolute number and ratio of metastatic lymph nodes in predicting postoperative survival for the International Federation of Gynecology and Obstetrics stage IA2 to IIA cervical cancer. Int J Gynecol Cancer. 2013;23(1):157-163.
26.
ChungCKNahhasWAStrykerJACurrySLAbtABMortelRAnalysis of factors contributing to treatment failures in stages IB and IIA carcinoma of the cervix. Am J Obstet Gynecol. 1980;138(5):550-556.
27.
LaiCHHsuehSHongJHet al.
Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery?Int J Gynecol Cancer. 1999;9(1):28-36.
